HRP20130173T1 - Farmaceutske formulacije ciklosporina - Google Patents
Farmaceutske formulacije ciklosporina Download PDFInfo
- Publication number
- HRP20130173T1 HRP20130173T1 HRP20130173AT HRP20130173T HRP20130173T1 HR P20130173 T1 HRP20130173 T1 HR P20130173T1 HR P20130173A T HRP20130173A T HR P20130173AT HR P20130173 T HRP20130173 T HR P20130173T HR P20130173 T1 HRP20130173 T1 HR P20130173T1
- Authority
- HR
- Croatia
- Prior art keywords
- drug
- formulation according
- released
- mini
- hours
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 21
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims 19
- 108010036949 Cyclosporine Proteins 0.000 title claims 19
- 229960001265 ciclosporin Drugs 0.000 title claims 18
- 229930182912 cyclosporin Natural products 0.000 title claims 8
- 229930105110 Cyclosporin A Natural products 0.000 title claims 5
- 238000009472 formulation Methods 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 18
- 239000002775 capsule Substances 0.000 claims 12
- 210000001072 colon Anatomy 0.000 claims 7
- 230000002496 gastric effect Effects 0.000 claims 5
- 210000003405 ileum Anatomy 0.000 claims 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 4
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 238000004090 dissolution Methods 0.000 claims 4
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 239000000284 extract Substances 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 239000000419 plant extract Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 229920000856 Amylose Polymers 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- BNJOZDZCRHCODO-UHFFFAOYSA-N dimethyloxalylglycine Chemical compound COC(=O)CNC(=O)C(=O)OC BNJOZDZCRHCODO-UHFFFAOYSA-N 0.000 claims 2
- -1 eflunomide Chemical compound 0.000 claims 2
- 239000003925 fat Substances 0.000 claims 2
- 235000019197 fats Nutrition 0.000 claims 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229960002474 hydralazine Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000001814 pectin Substances 0.000 claims 2
- 229960000292 pectin Drugs 0.000 claims 2
- 235000010987 pectin Nutrition 0.000 claims 2
- 229920001277 pectin Polymers 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- 244000144927 Aloe barbadensis Species 0.000 claims 1
- 235000002961 Aloe barbadensis Nutrition 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000019399 Colonic disease Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 244000237986 Melia azadirachta Species 0.000 claims 1
- 235000013500 Melia azadirachta Nutrition 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 244000170064 Myrciaria floribunda Species 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- 240000000851 Vaccinium corymbosum Species 0.000 claims 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims 1
- 229960001683 abetimus Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 235000011399 aloe vera Nutrition 0.000 claims 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 230000008953 bacterial degradation Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 235000021014 blueberries Nutrition 0.000 claims 1
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
- 150000001765 catechin Chemical class 0.000 claims 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims 1
- 235000005487 catechin Nutrition 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000004064 cosurfactant Substances 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims 1
- 229960002706 gusperimus Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000023569 ischemic bowel disease Diseases 0.000 claims 1
- 229960004488 linolenic acid Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 239000002018 neem oil Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 1
- 229960005330 pimecrolimus Drugs 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 239000002861 polymer material Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 claims 1
- 239000010681 turmeric oil Substances 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
Claims (19)
1. Oralna formulacija ciklosporina koja se sastoji od mini-kapsula koje imaju jezgru koja se sastoji od ciklosporina u obliku solubilizirane tekućine, s tim da mini-kapsule imaju profil oslobađanja koji omogućava da se predsolubilizirani ciklosporin oslobađa barem u kolonu, za primjenu u: liječenju bolesti kolona, naročito upalnih ili ishemijom potaknutih bolesti, ishemičnih bolesti crijeva, nekrotizirajućeg enterokolitisa, celijakije ili proktitisa, ulceroznog kolitisa i/ili Crohnove bolesti liječenju ili prevenciji upalne bolesti crijeva, reakcija transplantata protiv primatelja i gastrointestinalne reakcije transplantata protiv primatelja i /ili iritabilnog kolona.
2. Formulacija prema zahtjevu 1, naznačena time da mini-kapsula može biti jednoslojna ili višeslojna.
3. Formulacija prema jednom od prethodnih zahtjeva, naznačena time da mini-kapsule imaju profil oslobađanja da bi mogle oslobađati predsolubilizirani ciklosporin u ileumu i/ili tankom crijevu.
4. Formulacija prema jednom od prethodnih zahtjeva, naznačena time da je ciklosporin tipa ciklosporin A, s tim da je ciklosporin opcionalno prisutan u jezgri u koncentraciji od 2,5 do 25% w/w, pretežito u koncentraciji od 2,5 do 10% w/w.
5. Formulacija prema jednom od prethodnih zahtjeva za primjenu u liječenju ulceroznog kolitisa ili Crohnove bolesti, koja ima profil rastvaranja kada se ispituje u uređaju U.S.P. tip II (lopatice) na 37°C i 50 rpm, u puferu pH 6.8 na sljedeći način: do 4 sata: oslobođeno manje od ili oko 20% lijeka; 6 sati: oslobođeno manje od ili oko 35% lijeka; 8 sati: oslobođeno manje od ili oko 50% lijeka; 12 sati: oslobođeno manje od ili oko 60% lijeka; 18 sati: oslobođeno manje od ili oko 75% lijeka; i 24 sata: oslobođeno od oko 25% do oko 100% lijeka.
6. Formulacija prema jednom od zahtjeva 1 do 4 za primjenu u liječenju gastrointestinalne reakcije transplantata protiv primatelja, koja ima profil rastvaranja kada se ispituje u uređaju U.S.P. tip II (lopatice) na 37°C i 50 rpm, u puferu pH 6.8 na sljedeći način: 1 sat: oslobođeno manje od ili oko 20% lijeka; 4 sata: oslobođeno manje od ili oko 35% lijeka; 6 sati: oslobođeno manje od ili oko 50% lijeka; 12 sati: oslobođeno manje od ili oko 60% lijeka; 16 sati: oslobođeno manje od ili oko 75% lijeka; i 24 sata: oslobođeno od oko 25% do oko 100% lijeka.
7. Formulacija prema jednom od prethodnih zahtjeva, naznačena time da se ovojnica mini-kapsule oblaže slojem s modificiranim oslobađanjem, s tim da se opcionalno koristi polimerni materijal za postizanje modificiranog oslobađanja, primjerice bilo koja kombinacija dostupnih akrilnih, metakrilnih polimera i polimera na bazi etilceluloze (kao što su Eudragit i Surelease®) kao i drugi polimeri s prirodnim polisaharidima.
8. Formulacija prema zahtjevu 7, naznačena time da je polimerni materijal metakrilat, etilceluloza ili mješavina metakrilata i etilceluloze.
9. Formulacija prema zahtjevu 7 ili 8, naznačena time da sloj sadrži agens za poticanje rastvaranja kojeg razgrađuju bakterije koje su uobičajeno prisutne u donjem gastrointestinalnom sustavu, primjerice naznačeno time da se agens za poticanje rastvaranja odabire iz jednoga ili više iz skupine pektina, amiloze i alginata ili njihovih derivata.
10. Formulacija prema zahtjevu 7, 8 ili 9, naznačena time da jezgra sadrži ciklosporin A, otapalo, solubilizirajući agens i emulgator.
11. Formulacija prema jednom od prethodnih zahtjeva, naznačena time da se mini-kapsule dobiju iskorištavanjem površinskog naprezanja različitih otopina u postupku u kojem se otopina jezgre i otopina ovojnice ištrcavaju kroz otvor ili mlaznicu s jednim ili više otvora, određenog promjera, a podložno određenim frekvencijama i gravitacijskom toku se oblikuju u oblik kugle i upadaju u protok zraka za hlađenje ili u otopinu za hlađenje ili stvrdnjavanje, a vanjska ovojnica se želira ili skrućuje.
12. Formulacija prema jednom od prethodnih zahtjeva, naznačena time da se sastoji od tvrde želatizirane kapsule, sadržaja za isipanje ili tableta koja sadrži mini-kapsule, s tim da opcionalno mini-kapsule također sadrže pomoćne tvari radi povećanja terapijskog potencijala ciklosporina u ileumu i kolonu, s tim da se opcionalno pomoćne tvari za povećanja terapijskog potencijala ciklosporina u ileumu i kolonu odabiru iz jednoga ili više iz skupine apsorpcijskih limitatora, surfaktanta, kosurfaktanta, suotapala, esencijalnih masti kao što su omega 3 masti, prirodni biljni ekstrakti kao što su nim, ionski izmjenjive smole, antioksidansi, polieteri, stabilizatori, konzervansi, konjugacijski povezivač za razgradnju bakterija kao što su azo spojevi, polisaharidi kao što su amiloza, guar guma, pektin, kitozan, inulin i ciklodekstrini.
13. Primjena ciklosporina u proizvodnji lijekova za primjenu u: liječenju ili prevenciji upalne bolesti crijeva, reakcija transplantata protiv primatelja i gastrointestinalne reakcije transplantata protiv primatelja i /ili iritabilnog kolona; i/ili u liječenju ulcroznog kolitisa i/ili Crohnove bolesti, s tim da se lijek proizvodi tako da ciklosporin, sam ili u kombinaciji, stavlja u mini-kapsule ili mini-kuglice koje ciljaju oslobađanje barem u kolonu.
14. Formulacija prema jednom od zahtjeva 1 do 12, naznačena time da se ciklosporin primjenjuje u kombinaciji s drugom terapeutski ili profilaktični aktivnom cjelinom, s tim da se drugi aktivni lijek opcionalno odabire među kalcineurinskim inhibitorima, npr. abetimus, deforolimus, everolimus, gusperimus, pimekrolimus, sirolimus, takrolimus, temsirolimus, glukokortikosteroidi; citostaticima npr. anakinra, azatioprin, eflunomid, metotreksat, mikofenolna kiselina, talidomid; antitijelima npr. anti-CD3 OKT3 usmjerena na receptore T stanica; sirolimus, interferonima, opioidima, TNF(-vezujućim proteinima, npr. infliksimab, etnercept. adalimumab, kukumin i katekinima; i mikofenolat mofetilne kiseline, s tim da se drugi aktivni lijek opcionalno odabire među određenim prirodnim ekstraktima, npr. ulje nima, aloe vera, tripala, ulje kurkume i druga esencijalna ulja, npr. EPA, DHA, spojena linolenska kiselina (CLA) i drugi derivati istih, biljni ekstrakti, npr. ekstrakti bobica, npr. borovnica, aki, rezorkinolni/fenolni lipidi, resveratrol, flavanoidi i derivati istih, samostalno ili u kombinaciji, proteini, terapeutski peptidi, cjepiva, antitijela ili dijelovi istih, te također da se drugi lijek opcionalno odabire iz jednog od navedenih ili kombinacije takrolimusa, sirolimusa, hidralazina, DMOG-a, inhibitora propil i/ili asparaginil hidroksilaze, EPA, DHA, prirodnih biljnih ekstrakata, prirodnih morskih ekstrakata ili drugih bioloških i aktivnih cjelina, npr. siRNA konstrukti.
15. Formulacija prema zahtjevu 14, naznačena time da se terapeutski ili profilaktički aktivna cjelina odabire između hidralazina, DMOG-a i drugih inhibitora propil i/ili asparaginil hidroksilaze.
16. Formulacija prema zahtjevu 14 ili 15, naznačena time da su ciklosporin i terapeutski ili profilaktički aktivna cjelina zajedno zatvoreni u mikro-kapsulama ili mikro-kuglicama.
17. Formulacija prema zahtjevu 14 u kojoj je drugi aktivni lijek imunološki modulirajuća cjelina, primjerice antigen, ajuvant, emulzija, ulje ili sitna molekula i koji se koristi kao cjepivo, modulator oralne tolerancije ili modulator alergena.
18. Oralna formulacija ciklosporina koja sadrži dozu ciklosporina i najmanje jednu farmaceutski prihvatljivu pomoćnu tvar i koja oslobađa ciklosporin u ileumu i/ili kolonu, za primjenu u liječenju upalnih bolesti crijeva kao npr. ulcerozni kolitis, Crohnova bolest ili gastrointestinalna reakcija transplantata protiv primatelja, s tim da je formulacija u obliku mini-kapsula s krutim, polukrutim ili tekućim punjenjem koje se sastoje od jednog sloja ili više slojeva, s tim da mini-kapsule imaju profil oslobađanja da se predsolubilizirani ciklosporin oslobađa u ileumu i/ili kolonu.
19. Formulacija prema zahtjevu 18 koja se koristi u liječenju i prevenciji gastrointestinalne reakcije transplantata protiv primatelja i osigurava značajno oslobađanje u cijelom gastrointestinalnom sustavu od tankog crijeva do kolona.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90749007P | 2007-04-04 | 2007-04-04 | |
US649808P | 2008-01-16 | 2008-01-16 | |
PCT/IE2008/000038 WO2008122965A2 (en) | 2007-04-04 | 2008-04-04 | Pharmaceutical cyclosporin compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20130173T1 true HRP20130173T1 (hr) | 2013-04-30 |
Family
ID=39745242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130173AT HRP20130173T1 (hr) | 2007-04-04 | 2013-02-28 | Farmaceutske formulacije ciklosporina |
Country Status (11)
Country | Link |
---|---|
US (11) | US8535713B2 (hr) |
EP (5) | EP2061440A2 (hr) |
JP (6) | JP2010523555A (hr) |
CN (6) | CN103120653B (hr) |
CA (3) | CA2683407C (hr) |
CY (1) | CY1113882T1 (hr) |
DK (1) | DK2079456T3 (hr) |
ES (3) | ES2400964T3 (hr) |
HR (1) | HRP20130173T1 (hr) |
PT (1) | PT2079456E (hr) |
WO (3) | WO2008122965A2 (hr) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103120653B (zh) | 2007-04-04 | 2015-09-30 | 希格默伊德药业有限公司 | 一种口服药物组合物 |
JP2010527285A (ja) * | 2007-04-26 | 2010-08-12 | シグモイド・ファーマ・リミテッド | 複数のミニカプセルの製造 |
US20100239665A1 (en) * | 2007-05-01 | 2010-09-23 | Ivan Coulter | Pharmaceutical nimodipine compositions |
US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
LT2364360T (lt) | 2008-11-13 | 2017-08-10 | Nogra Pharma Limited | Priešprasmės kompozicijos ir jų gavimo bei panaudojimo būdai |
EP3300723A1 (en) | 2009-05-18 | 2018-04-04 | Sigmoid Pharma Limited | Composition comprising oil drops |
JP5911799B2 (ja) * | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | ポリマーマトリックスおよび油相を含んで成る免疫調節組成物 |
WO2015161139A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
KR101245078B1 (ko) * | 2010-11-11 | 2013-03-18 | 부산대학교 산학협력단 | 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물 |
GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
EP2688557B1 (en) | 2011-03-23 | 2017-08-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9314437B2 (en) | 2011-04-22 | 2016-04-19 | Napo Pharmaceuticals, Inc. | Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (NDGA) |
CA3182519A1 (en) * | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
US9561241B1 (en) * | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
WO2013124416A1 (en) * | 2012-02-23 | 2013-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
CN109172816A (zh) * | 2012-03-29 | 2019-01-11 | 塞拉拜姆有限责任公司 | 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂 |
EP2854537A4 (en) * | 2012-05-04 | 2016-04-06 | Univ Chicago | INCREASES IN BIOAVAILABILITY OF ORAL METHYLNALTREXONE BY PHOSPHATIDYLCHOLINE FORMULATION |
DE102012105528A1 (de) * | 2012-06-25 | 2014-01-02 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur Freisetzung von Wirkstoffen |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
JP5992247B2 (ja) * | 2012-08-13 | 2016-09-14 | 国立大学法人大阪大学 | 核酸医薬経口製剤 |
JP6062802B2 (ja) * | 2012-08-23 | 2017-01-18 | 日清ファルマ株式会社 | キトサン含有組成物及びキトサンコーティング組成物 |
GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
KR20150143498A (ko) * | 2013-03-15 | 2015-12-23 | 갈레온 파마슈티칼스, 인코포레이티드 | 신규 호흡 조절 제어 화합물 및 그의 사용방법 |
AU2014262163A1 (en) | 2013-05-03 | 2015-11-19 | Selecta Biosciences, Inc. | Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance |
US9415110B1 (en) | 2013-05-08 | 2016-08-16 | The Arizona Board of Regents on behalf of the Univeristy of Arizona | Method and compositions for targeted drug delivery to the lower GI tract |
CN104127466B (zh) * | 2013-08-23 | 2018-05-22 | 江苏省中医药研究院 | 一种淫羊藿总黄酮口服肠溶制剂及其应用 |
CN104548063A (zh) * | 2013-10-29 | 2015-04-29 | 中国科学院上海有机化学研究所 | 一种免疫抑制剂在制备线粒体丝氨酸/苏氨酸蛋白磷酸酶抑制剂中的用途 |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
GB201319792D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
HUP1300647A2 (hu) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik |
US20160287533A1 (en) * | 2013-11-27 | 2016-10-06 | Research Foundation Of The City University Of New York | Activity Enhancing Curcumin Compositions and Methods of Use |
CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
GB201400442D0 (en) * | 2014-01-10 | 2014-02-26 | Sigmoid Pharma Ltd | Compositions for use in the treatment of ulcerative colitis |
CN106999477B (zh) * | 2014-06-30 | 2020-04-10 | 萨利克斯药品公司 | 用于重复治疗肠易激综合征(ibs)的方法 |
KR20170021350A (ko) | 2014-07-01 | 2017-02-27 | 프로비 유에스에이, 인코포레이티드 | 이층 이중 방출 프로바이오틱 정제 |
KR102492411B1 (ko) * | 2014-08-04 | 2023-01-26 | 디비브이 테크놀로지스 (소시에떼 아노님) | 식품 알레르겐에 대한 조성물 |
CN107072237B (zh) | 2014-09-02 | 2021-12-14 | 谱赛科有限责任公司 | 甜菊提取物 |
CN107073091A (zh) | 2014-09-07 | 2017-08-18 | 西莱克塔生物科技公司 | 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物 |
CN104224732B (zh) * | 2014-09-29 | 2017-06-30 | 江苏大学 | 一种口服骨架型环孢素a缓释微丸制剂及其制备方法 |
CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
EP3215127B1 (en) * | 2014-11-07 | 2020-10-28 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
WO2016105498A1 (en) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
CN104473907A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种他克莫司的口服缓释制剂 |
AU2016257813B2 (en) | 2015-05-01 | 2021-05-13 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
WO2017167997A1 (en) | 2016-03-31 | 2017-10-05 | Vhsquared Limited | Compositions |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
TR201610597A2 (tr) * | 2016-07-29 | 2016-12-21 | Kamil Varlik Erel | Mide ve bağırsak içine yerleştirilen tüp veya sondalardan kullanıma uygun ilaç |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
JP7237834B2 (ja) * | 2016-12-14 | 2023-03-13 | ビオラ・セラピューティクス・インコーポレイテッド | 消化管疾病のil-12/il-23阻害薬による治療 |
AU2017378406A1 (en) | 2016-12-14 | 2019-06-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
EP4233902A3 (en) * | 2016-12-14 | 2024-02-28 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
EP3554541B1 (en) * | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018137686A1 (en) * | 2017-01-26 | 2018-08-02 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
CN110612122A (zh) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物 |
CA3054156A1 (en) * | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
WO2018183934A1 (en) * | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
EP3600416B1 (en) * | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
EP3638211B1 (en) * | 2017-06-14 | 2023-11-29 | SpecGx LLC | Delayed sustained release pharmaceutical compositions |
US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
EP3668544A1 (en) * | 2017-08-15 | 2020-06-24 | Progenity, Inc. | Treatment of inflammatory disease using ingestible device to release immune modulator |
ES2938608T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización |
WO2019118778A1 (en) * | 2017-12-14 | 2019-06-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a s1p modulator |
WO2019139891A1 (en) | 2018-01-09 | 2019-07-18 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
CN108379238B (zh) * | 2018-01-17 | 2020-07-14 | 南昌大学 | 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法 |
AU2019232145A1 (en) * | 2018-03-07 | 2020-10-01 | Teagasc - The Agriculture And Food Development Authority | A composition for type II diabetics and for use in providing sustained energy release over time |
US10835489B2 (en) | 2018-03-09 | 2020-11-17 | University Of Saskatchewan | Modified release formulations of mycophenolate mofetil |
KR20200134271A (ko) * | 2018-03-19 | 2020-12-01 | 제미니 라보라토리스, 엘엘씨 | 면역억제성 투약형 및 사용 방법 |
US11654184B2 (en) | 2018-03-20 | 2023-05-23 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
WO2020106330A1 (en) * | 2018-07-18 | 2020-05-28 | Pillsy, Inc. | Smart drug delivery and monitoring device, kit, and method of use for pill compounds |
WO2020041378A1 (en) * | 2018-08-22 | 2020-02-27 | Bacainn Therapeutics, Inc. | Cyclosporine compositions and methods of use |
CN110934831B (zh) * | 2018-09-25 | 2021-09-14 | 天津大学 | 二甲基乙二酰甘氨酸-白藜芦醇核壳型纳米材料及其制备方法 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10752642B1 (en) | 2019-04-30 | 2020-08-25 | George Mason University | Macrocyclic lactones |
US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
TW202120521A (zh) | 2019-08-16 | 2021-06-01 | 美商應用分子運輸公司 | 組合物、配方及介白素生產及純化 |
CN114650833A (zh) | 2019-09-13 | 2022-06-21 | 芬奇治疗控股有限责任公司 | 用于治疗孤独症谱群障碍的组合物和方法 |
US20240131082A1 (en) | 2019-10-18 | 2024-04-25 | Finch Therapeutics Holdings Llc | Compositions and Methods for Delivering a Bacterial Metabolite to a Subject |
WO2021097288A1 (en) | 2019-11-15 | 2021-05-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating neurodegenerative diseases |
CN111297953A (zh) * | 2019-12-20 | 2020-06-19 | 卓和药业集团有限公司 | 一种预防肾脏移植后移植排斥反应的复方制剂 |
WO2021142347A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for non-alcoholic steatohepatitis (nash) |
WO2021142353A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv) |
WO2021142358A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatic encephalopathy (he) |
EP4117718A4 (en) * | 2020-03-09 | 2024-05-08 | Univ Houston System | INFLAMMATORY BOWEL DISEASE (IBD)-ASSOCIATED STEM CELLS, AGENTS TARGETING IBD-ASSOCIATED STEM CELLS AND RELATED USES THEREOF |
US20230201265A1 (en) | 2020-03-31 | 2023-06-29 | Finch Therapeutics Holdings Llc | Compositions comprising non-viable fecal microbiota and methods of use thereof |
US11426353B2 (en) * | 2020-06-24 | 2022-08-30 | 13400719 Canada Inc. | Composite coating for an active agent |
US11666560B2 (en) | 2020-09-24 | 2023-06-06 | George Mason University | Anti-fibrotic agent |
KR20230106657A (ko) * | 2020-11-10 | 2023-07-13 | 메드리젠 엘엘씨 | 제형, 방법, 키트, 및 투여형 |
JP2023553843A (ja) * | 2020-11-30 | 2023-12-26 | ロイヤル メルボルン インスティチュート オブ テクノロジー | 経口の治療的な送達 |
WO2022178294A1 (en) | 2021-02-19 | 2022-08-25 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
ES2924573B2 (es) * | 2021-03-18 | 2024-04-24 | Aora Health S L | Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal |
WO2023043854A1 (en) * | 2021-09-14 | 2023-03-23 | Nulixir Inc. | Alimentary-related particles, production methods, and production apparatus |
CN114916591A (zh) * | 2022-06-09 | 2022-08-19 | 江西维尔宝食品生物有限公司 | 一种起酥性烘焙专用可塑性粉末油脂组合物 |
US11806430B1 (en) | 2023-02-24 | 2023-11-07 | King Faisal University | Rectal gel with date palm phenolics and vanillic acid |
CN116650444B (zh) * | 2023-07-31 | 2023-10-31 | 国药集团川抗制药有限公司 | 一种他克莫司缓释药物及其制备方法 |
Family Cites Families (216)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3971852A (en) | 1973-06-12 | 1976-07-27 | Polak's Frutal Works, Inc. | Process of encapsulating an oil and product produced thereby |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IT1090703B (it) | 1976-12-03 | 1985-06-26 | Scherer Ltd R P | Perfezionamento nelle composizioni utili quali veicolo per farmaci |
DE2907460A1 (de) | 1978-03-07 | 1979-09-13 | Sandoz Ag | Neue resorbierbare galenische kompositionen |
US4279632A (en) | 1979-05-08 | 1981-07-21 | Nasa | Method and apparatus for producing concentric hollow spheres |
IT1148784B (it) * | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
JPS6415Y2 (hr) | 1981-05-29 | 1989-01-05 | ||
JPS5813508A (ja) | 1981-07-14 | 1983-01-26 | Taiho Yakuhin Kogyo Kk | ポリグリセロール飽和脂肪酸エステルを含む経口薬剤組成物 |
JPS5877810A (ja) | 1981-11-01 | 1983-05-11 | Taiho Yakuhin Kogyo Kk | ポリグリセロ−ル不飽和脂肪酸エステルを含む経口薬剤組成物 |
DE3224619A1 (de) | 1981-07-14 | 1983-05-19 | Freund Industrial Co., Ltd., Tokyo | Orale pharmazeutische zusammensetzung |
US4481157A (en) | 1982-04-27 | 1984-11-06 | Morishita Jintan Co., Ltd. | Method and apparatus for production of microcapsules |
US4597959A (en) | 1982-04-30 | 1986-07-01 | Arthur Barr | Sustained release breath freshener, mouth and palate coolant wafer composition and method of use |
US4422985A (en) | 1982-09-24 | 1983-12-27 | Morishita Jintan Co., Ltd. | Method and apparatus for encapsulation of a liquid or meltable solid material |
JPS5988420A (ja) | 1982-11-12 | 1984-05-22 | Teisan Seiyaku Kk | シ−ムレスカプセル化ニフエジピン製剤 |
JPS5988420U (ja) | 1982-12-04 | 1984-06-15 | 有限会社三和ボタン店 | 学生服の詰襟構造 |
JPS59131355A (ja) * | 1983-01-17 | 1984-07-28 | 森下仁丹株式会社 | 多重軟カプセルの製法 |
HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
JPS6115A (ja) | 1984-06-12 | 1986-01-06 | Kyowa Hakko Kogyo Co Ltd | リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS61115462A (ja) | 1984-11-13 | 1986-06-03 | Denka Seiyaku Kk | 甘味増強ステビア葉の製法 |
JPS61151119A (ja) | 1984-12-24 | 1986-07-09 | Taisho Pharmaceut Co Ltd | ソフトカプセル |
US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
US4658441A (en) * | 1985-12-13 | 1987-04-21 | Smith Steven A | One piece thumb support and protector |
EP0241806A1 (en) | 1986-04-14 | 1987-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Sustained-release transdermal delivery preparations |
US4857335A (en) | 1987-03-27 | 1989-08-15 | Lim Technology Laboratories, Inc. | Liquid controlled release formulations and method of producing same via multiple emulsion process |
WO1989001772A1 (en) | 1987-09-03 | 1989-03-09 | University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
US4910191A (en) * | 1988-06-28 | 1990-03-20 | Merrell Dow Pharmaceuticals Inc. | 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
GB2222770B (en) | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
WO1990006775A1 (en) | 1988-12-14 | 1990-06-28 | Liposome Technology, Inc. | A novel nonphospholipid liposome composition for sustained release of drugs |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
JP2806564B2 (ja) * | 1989-07-20 | 1998-09-30 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
US5260071A (en) | 1989-12-18 | 1993-11-09 | Lemelson Jerome H | Drug units and methods for using same |
BE1003677A3 (nl) | 1990-01-29 | 1992-05-19 | Schacht Etienne | Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen. |
IL98087A (en) | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Preparation for dispensing drugs in the colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
JP3179132B2 (ja) | 1990-07-04 | 2001-06-25 | 塩野義製薬株式会社 | 非粘着性皮膜形成法 |
US5102668A (en) | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5418010A (en) | 1990-10-05 | 1995-05-23 | Griffith Laboratories Worldwide, Inc. | Microencapsulation process |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
ATE161707T1 (de) | 1991-06-28 | 1998-01-15 | Univ Brown Res Found | Kapselextrusionssysteme |
JP3313124B2 (ja) | 1991-07-31 | 2002-08-12 | 森下仁丹株式会社 | 親水性物質を内容物とするシームレスカプセルおよびその製法 |
JPH0549899A (ja) | 1991-08-09 | 1993-03-02 | Japan Tobacco Inc | ビーズ及びこれを製造するための液滴生成装置 |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
AU666895B2 (en) | 1991-12-30 | 1996-02-29 | Hercules Incorporated | High load spray dry encapsulation |
AU3343093A (en) | 1992-01-17 | 1993-08-03 | Alfatec-Pharma Gmbh | Pellets containing peptide drugs, their manufacture and use |
DE4201179A1 (de) | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung |
US5571533A (en) | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
DE69324523T2 (de) * | 1992-06-12 | 1999-09-09 | Kao Corp | Badezusatzzusammensetzung enthaltend oberflächenaktive Mittel enthaltende nahtlose Kapsel und Verfahren zur Herrstellung der Kapsel |
JP3405746B2 (ja) | 1992-10-28 | 2003-05-12 | フロイント産業株式会社 | シームレスカプセルの製造方法 |
DE69332031T2 (de) | 1993-01-08 | 2002-12-19 | Csl Ltd | Impfstoffpräparate |
GB9300875D0 (en) | 1993-01-18 | 1993-03-10 | Ucb Sa | Nanocapsule containing pharmaceutical compositions |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5686105A (en) * | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US5914132A (en) | 1993-02-26 | 1999-06-22 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US5843347A (en) | 1993-03-23 | 1998-12-01 | Laboratoire L. Lafon | Extrusion and freeze-drying method for preparing particles containing an active ingredient |
DK66493D0 (da) | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
CN1077800C (zh) | 1993-07-01 | 2002-01-16 | 韩美药品工业株式会社 | 环孢菌素软胶囊组合物 |
FR2707184B1 (fr) | 1993-07-08 | 1995-08-11 | Rhone Poulenc Nutrition Animal | Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique. |
US6204243B1 (en) * | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
DE4329503A1 (de) * | 1993-09-01 | 1995-03-02 | Galenik Labor Freiburg Gmbh | Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa |
DE4332041C2 (de) | 1993-09-21 | 1997-12-11 | Rentschler Arzneimittel | Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
WO1995022343A1 (fr) | 1994-02-17 | 1995-08-24 | Shiseido Company, Ltd. | Composition d'emulsion a base de cyclosporine |
US5498439A (en) | 1994-03-04 | 1996-03-12 | Arnhem, Inc. | Process for encapsulating the flavor with colloid gel matrix |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
AU689250B2 (en) | 1994-04-22 | 1998-03-26 | Astellas Pharma Inc. | Colon-specific drug release system |
GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
FR2721510B1 (fr) | 1994-06-22 | 1996-07-26 | Rhone Poulenc Rorer Sa | Nanoparticules filtrables dans des conditions stériles. |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE4430127A1 (de) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat |
US5650232A (en) * | 1994-10-07 | 1997-07-22 | Warner-Lambert Company | Method for making seamless capsules |
FR2725623A1 (fr) * | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5529783A (en) * | 1994-12-19 | 1996-06-25 | Mcneil-Ppc, Inc. | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan |
KR0167613B1 (ko) | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5674495A (en) * | 1995-02-27 | 1997-10-07 | Purdue Research Foundation | Alginate-based vaccine compositions |
US5595757A (en) * | 1995-03-29 | 1997-01-21 | Warner-Lambert Company | Seamless capsules |
US5665386A (en) | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5767153A (en) | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
IE80467B1 (en) | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
SE504582C2 (sv) | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyklosporinkomposition baserad på en L2-fas |
JP2682818B2 (ja) | 1995-08-04 | 1997-11-26 | 大成化工株式会社 | 害虫誘引阻止材 |
RO119815B1 (ro) | 1995-08-25 | 2005-04-29 | Sangstat Medical Corporation | Compoziţie orală cu ciclosporină |
EP0760237A1 (en) * | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
JP3759986B2 (ja) * | 1995-12-07 | 2006-03-29 | フロイント産業株式会社 | シームレスカプセルおよびその製造方法 |
EP0876142B1 (en) | 1996-01-16 | 2001-09-26 | Advanced Polymer Systems, Inc. | Topical delivery of drugs to the lower gastrointestinal tract |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US5686133A (en) * | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5958876A (en) | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
KR0183449B1 (ko) * | 1996-06-19 | 1999-05-01 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 |
WO1998018610A1 (en) | 1996-10-28 | 1998-05-07 | Lengerich Bernhard H Van | Embedding and encapsulation of controlled release particles |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
JP2001515491A (ja) | 1997-03-12 | 2001-09-18 | アボツト・ラボラトリーズ | 親油性化合物の投与のための親油性二成分系 |
DZ2479A1 (fr) * | 1997-05-05 | 2003-02-01 | Pfizer | Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant. |
AU7201998A (en) | 1997-05-06 | 1998-11-27 | Zhi Liu | Drug delivery system |
JP4102459B2 (ja) * | 1997-05-14 | 2008-06-18 | 森下仁丹株式会社 | 生体高分子を合成するシームレスカプセルおよびその製造方法 |
SE9702533D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
CA2294031E (en) | 1997-07-29 | 2012-04-03 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
ES2137862B1 (es) | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
JP3090198B2 (ja) * | 1997-08-21 | 2000-09-18 | 日本電気株式会社 | 半導体装置の構造およびその製造方法 |
HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
WO1999022719A1 (fr) | 1997-10-30 | 1999-05-14 | Morishita Jintan Co., Ltd. | Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication |
US5891845A (en) | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
IT1296585B1 (it) | 1997-11-28 | 1999-07-14 | Uni Di Pavia | Microcapsule contenenti materiale seminale per l'inseminazione strumentale nella specie suina |
US6509346B2 (en) * | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
US6174466B1 (en) | 1998-05-08 | 2001-01-16 | Warner-Lambert Company | Methods for making seamless capsules |
DE19821951A1 (de) * | 1998-05-15 | 1999-11-18 | Basf Ag | Cyclosporin-Zubereitungen |
JPH11322587A (ja) | 1998-05-18 | 1999-11-24 | Sumitomo Chem Co Ltd | 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物 |
KR100336090B1 (ko) | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
MXPA01003197A (es) | 1998-09-28 | 2004-04-21 | Warner Lambert Co | Suministro enterico y colonico utilizando capsulas de chpm. |
DE19848849A1 (de) | 1998-10-22 | 2000-04-27 | Knoll Ag | Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz |
KR100602725B1 (ko) | 1998-12-11 | 2006-07-20 | 파마솔루션스, 인코포레이티드 | 물에서 불충분하게 용해되는 약제를 위한 자가-유화용조성물 |
JP3039863B1 (ja) | 1998-12-25 | 2000-05-08 | 不二精工株式会社 | ロッキングプレス装置 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
JP2000247911A (ja) | 1999-02-26 | 2000-09-12 | Hisamitsu Pharmaceut Co Inc | 大腸用吸収促進剤 |
JP2000302654A (ja) | 1999-04-16 | 2000-10-31 | Kao Corp | 歯磨組成物の製造法 |
US8663692B1 (en) | 1999-05-07 | 2014-03-04 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
WO2000069420A1 (en) | 1999-05-14 | 2000-11-23 | Coraltis Ltd. | Pulse-delivery oral compositions |
EP1184038B1 (en) * | 1999-06-09 | 2005-12-28 | Mochida Pharmaceutical Co., Ltd. | System for release in lower digestive tract |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
BR0012869A (pt) | 1999-07-30 | 2002-05-21 | Smithkline Beecham Plc | Forma de dosagem farmacêutica de componentes múltiplos |
EP1227793A1 (en) | 1999-11-02 | 2002-08-07 | Cipla Ltd. | Cyclosporin formulation |
US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
JP2004504264A (ja) * | 2000-01-07 | 2004-02-12 | ユニバーシティ オブ シンシナティ | Th1又はth2リンパ球に制御される免疫応答の選択的活性化 |
US6544646B2 (en) | 2000-04-27 | 2003-04-08 | Verion Inc. | Zero order release and temperature-controlled microcapsules and process for the preparation thereof |
US6656470B2 (en) | 2000-05-12 | 2003-12-02 | Pharmacia & Upjohn Company | Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
GB0018527D0 (en) | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
ATE477804T1 (de) | 2001-03-15 | 2010-09-15 | Soligenix Inc | Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden |
US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
US20030083286A1 (en) | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US6951655B2 (en) | 2001-10-11 | 2005-10-04 | Imi Biomed, Inc. | Pro-micelle pharmaceutical compositions |
US20040126428A1 (en) | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
US20050129718A1 (en) | 2001-12-20 | 2005-06-16 | Sherman Bernard C. | Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
AU2002348747A1 (en) | 2002-01-10 | 2003-07-24 | Firmenich Sa | Process for the preparation of extruded delivery systems |
GB0203421D0 (en) * | 2002-02-13 | 2002-04-03 | Alizyme Therapeutics Ltd | Composition |
US6974592B2 (en) | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
JP4226846B2 (ja) | 2002-06-07 | 2009-02-18 | キャタレント・ジャパン株式会社 | 口腔内で崩壊可能なソフトカプセル剤 |
GB2391473B (en) | 2002-08-02 | 2004-07-07 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
CA2499423A1 (en) | 2002-09-04 | 2004-03-18 | Niraj Vasisht | Microencapsulation of oxygen or water sensitive materials |
WO2004042024A2 (en) | 2002-11-01 | 2004-05-21 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
US7524515B2 (en) | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
WO2004064997A1 (en) | 2003-01-23 | 2004-08-05 | Inotech Ag | New microcapsules useful as extraction means in particular for extracting water or soil contaminants |
US20060167435A1 (en) | 2003-02-18 | 2006-07-27 | Adamis Anthony P | Transscleral drug delivery device and related methods |
EP1608347B1 (en) * | 2003-03-28 | 2014-08-13 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
ES2398235T3 (es) * | 2003-04-04 | 2013-03-14 | Pah Usa 15 Llc | Emulsiones de aceite en agua microfluidizadas y composiciones de vacunas |
US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
EP1663216B1 (en) * | 2003-08-29 | 2011-11-02 | Veloxis Pharmaceuticals A/S | Modified release compositions comprising tacrolimus |
US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
NZ546974A (en) | 2003-11-21 | 2008-06-30 | Commw Scient Ind Res Org | Gastrointestinal tract delivery systems |
EP1697511A4 (en) | 2003-12-11 | 2007-11-21 | Vaxdesign Corp | IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME |
CN1268325C (zh) | 2004-01-18 | 2006-08-09 | 浙江大学 | 三重复合微球制剂及其制备方法 |
AU2005210668A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
PE20060003A1 (es) | 2004-03-12 | 2006-03-01 | Smithkline Beecham Plc | Formulacion farmaceutica polimerica para moldear por inyeccion |
FR2867395B1 (fr) | 2004-03-15 | 2006-06-16 | Rhodia Chimie Sa | Emulsion sechee, son procede de preparation, et ses utilisations |
EP1576881A1 (en) * | 2004-03-15 | 2005-09-21 | Urea Casale S.A. | Process for the production of granules or pellets containing filamentary fungi |
RS52233B (en) | 2004-05-07 | 2012-10-31 | Nycomed Gmbh | THE PHARMACEUTICAL DOSAGE FORM CONTAINING GRANULES AND ITS PRODUCTION PROCEDURE |
GB0413730D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
WO2006002365A2 (en) | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
GB0417481D0 (en) | 2004-08-05 | 2004-09-08 | Etiologics Ltd | Combination therapy |
WO2006026592A2 (en) | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Oral administration of poorly absorbed drugs, methods and compositions related thereto |
US7718624B2 (en) * | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
EP1789090A2 (en) | 2004-09-02 | 2007-05-30 | Bionaut Pharmaceuticals, Inc. | Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors |
IE20050639A1 (en) * | 2004-09-27 | 2006-09-06 | Sigmoid Biotechnologies Ltd | Minicapsule formulations |
US20080113031A1 (en) | 2004-09-27 | 2008-05-15 | Joey Moodley | Minicapsule Formulations |
FI20041425A0 (fi) * | 2004-11-05 | 2004-11-05 | Orion Corp | Transmukosaalinen veterinäärinen koostumus |
EP1868567A4 (en) | 2005-03-29 | 2010-09-29 | Mcneil Ppc Inc | COMPOSITIONS WITH HYDROPHILIC DRUGS IN A HYDROPHOBIC MEDIUM |
JP2008535921A (ja) | 2005-04-12 | 2008-09-04 | エラン・ファルマ・インターナショナル・リミテッド | シクロスポリンを含むナノ粒子および放出調節された組成物 |
JP2009502841A (ja) | 2005-07-26 | 2009-01-29 | グラクソ グループ リミテッド | 脂質をベースにした製剤の腸溶性ポリマー中へのカプセル化 |
EP1909771A1 (en) * | 2005-08-02 | 2008-04-16 | Miv Therapeutics Inc. | Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same |
US7842312B2 (en) * | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
JP5398268B2 (ja) | 2006-02-09 | 2014-01-29 | アルバ セラピューティクス コーポレーション | タイトジャンクション・エフェクター用製剤 |
US20070274932A1 (en) * | 2006-05-15 | 2007-11-29 | The Procter & Gamble Company | Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US20080124279A1 (en) * | 2006-11-17 | 2008-05-29 | Antoine Andremont | Colonic delivery using Zn/pectin beads with a Eudragit coating |
CN103120653B (zh) | 2007-04-04 | 2015-09-30 | 希格默伊德药业有限公司 | 一种口服药物组合物 |
US20100239665A1 (en) | 2007-05-01 | 2010-09-23 | Ivan Coulter | Pharmaceutical nimodipine compositions |
US9833510B2 (en) | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
WO2009002533A1 (en) | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
US8865692B2 (en) | 2007-11-13 | 2014-10-21 | Meritage Pharma, Inc | Compositions for the treatment of gastrointestinal inflammation |
-
2008
- 2008-04-04 CN CN201210536527.7A patent/CN103120653B/zh active Active
- 2008-04-04 CN CN201510093514.0A patent/CN105030729A/zh active Pending
- 2008-04-04 CN CN2008800162210A patent/CN101686948B/zh active Active
- 2008-04-04 ES ES08719896T patent/ES2400964T3/es active Active
- 2008-04-04 EP EP08719897A patent/EP2061440A2/en not_active Withdrawn
- 2008-04-04 PT PT87198966T patent/PT2079456E/pt unknown
- 2008-04-04 EP EP08719898A patent/EP2066309B1/en active Active
- 2008-04-04 JP JP2010501662A patent/JP2010523555A/ja active Pending
- 2008-04-04 CA CA2683407A patent/CA2683407C/en active Active
- 2008-04-04 CN CN201310199898.5A patent/CN103316326B/zh active Active
- 2008-04-04 EP EP11174159A patent/EP2409691A1/en not_active Withdrawn
- 2008-04-04 CA CA2683415A patent/CA2683415C/en active Active
- 2008-04-04 CA CA002683409A patent/CA2683409A1/en not_active Abandoned
- 2008-04-04 CN CN2008800183170A patent/CN101990429A/zh active Pending
- 2008-04-04 ES ES08719898T patent/ES2393814T3/es active Active
- 2008-04-04 JP JP2010501660A patent/JP5553747B2/ja active Active
- 2008-04-04 WO PCT/IE2008/000038 patent/WO2008122965A2/en active Application Filing
- 2008-04-04 US US12/594,534 patent/US8535713B2/en active Active
- 2008-04-04 ES ES11169711.6T patent/ES2524345T3/es active Active
- 2008-04-04 US US12/594,542 patent/US9114071B2/en active Active
- 2008-04-04 DK DK08719896.6T patent/DK2079456T3/da active
- 2008-04-04 EP EP11169711.6A patent/EP2380564B1/en active Active
- 2008-04-04 WO PCT/IE2008/000040 patent/WO2008122967A2/en active Application Filing
- 2008-04-04 US US12/594,553 patent/US8911777B2/en not_active Expired - Fee Related
- 2008-04-04 EP EP08719896A patent/EP2079456B1/en active Active
- 2008-04-04 JP JP2010501661A patent/JP2010523554A/ja not_active Withdrawn
- 2008-04-04 CN CN200880016191A patent/CN101677964A/zh active Pending
- 2008-04-04 WO PCT/IE2008/000039 patent/WO2008122966A2/en active Application Filing
-
2012
- 2012-04-06 US US13/441,780 patent/US9844513B2/en not_active Expired - Fee Related
-
2013
- 2013-02-28 HR HRP20130173AT patent/HRP20130173T1/hr unknown
- 2013-03-05 CY CY20131100205T patent/CY1113882T1/el unknown
- 2013-07-15 US US13/942,492 patent/US9387179B2/en active Active
-
2014
- 2014-07-22 JP JP2014149027A patent/JP6059688B2/ja active Active
-
2015
- 2015-06-29 US US14/754,503 patent/US9585844B2/en active Active
- 2015-11-11 JP JP2015221221A patent/JP6149090B2/ja active Active
-
2016
- 2016-02-23 US US15/051,356 patent/US9675558B2/en active Active
-
2017
- 2017-01-19 US US15/410,448 patent/US10434139B2/en active Active
- 2017-05-02 JP JP2017091572A patent/JP2017160241A/ja active Pending
- 2017-05-16 US US15/596,759 patent/US10434140B2/en active Active
-
2019
- 2019-07-11 US US16/509,201 patent/US20200009218A1/en not_active Abandoned
- 2019-07-31 US US16/528,007 patent/US20200009219A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130173T1 (hr) | Farmaceutske formulacije ciklosporina | |
AU2020203240B2 (en) | Formulations | |
US20180042989A1 (en) | Immunomodulatory compositions | |
US9980902B2 (en) | Method for treating intestinal fibrosis | |
EP2471518B1 (en) | Composition comprising oil drops | |
JP2010523553A5 (hr) | ||
AU2014345543A1 (en) | Formulations | |
CA2935268A1 (en) | Compositions for use in the treatment of ulcerative colitis | |
ES2858517T3 (es) | Composiciones que comprenden ciclosporina | |
EA040614B1 (ru) | Составы |